BOLT Valuation

Bolt Biotherapeutics Inc

Add to Watchlist

Advanced Chart

5.340

-0.104(-1.910%)1D

Overview
Forecast
Valuation
Earnings

BOLT Relative Valuation

BOLT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BOLT is overvalued; if below, it's undervalued.

Historical Valuation

Bolt Biotherapeutics Inc (BOLT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -1.67. The fair price of Bolt Biotherapeutics Inc (BOLT) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 5.44 USD , Bolt Biotherapeutics Inc is Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：5.44

Fair

Undervalued

-0.21

Trailing

Forward

0.00

EV/EBITDA

Bolt Biotherapeutics Inc. (BOLT) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.65. The thresholds are as follows: Strongly Undervalued below -7.46, Undervalued between -7.46 and -4.06, Fairly Valued between 2.75 and -4.06, Overvalued between 2.75 and 6.15, and Strongly Overvalued above 6.15. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.01

EV/EBIT

Bolt Biotherapeutics Inc. (BOLT) has a current EV/EBIT of 0.01. The 5-year average EV/EBIT is -0.63. The thresholds are as follows: Strongly Undervalued below -7.56, Undervalued between -7.56 and -4.09, Fairly Valued between 2.83 and -4.09, Overvalued between 2.83 and 6.29, and Strongly Overvalued above 6.29. The current Forward EV/EBIT of 0.01 falls within the Historic Trend Line -Fairly Valued range.

0.00

Bolt Biotherapeutics Inc. (BOLT) has a current PS of 0.00. The 5-year average PS is 59.63. The thresholds are as follows: Strongly Undervalued below -165.04, Undervalued between -165.04 and -52.71, Fairly Valued between 171.96 and -52.71, Overvalued between 171.96 and 284.30, and Strongly Overvalued above 284.30. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Bolt Biotherapeutics Inc. (BOLT) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.12. The thresholds are as follows: Strongly Undervalued below -10.51, Undervalued between -10.51 and -6.31, Fairly Valued between 2.08 and -6.31, Overvalued between 2.08 and 6.27, and Strongly Overvalued above 6.27. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Bolt Biotherapeutics Inc. (BOLT) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

Bolt Biotherapeutics Inc (BOLT) has a current Price-to-Book (P/B) ratio of 0.25. Compared to its 3-year average P/B ratio of 0.31 , the current P/B ratio is approximately -19.00% higher. Relative to its 5-year average P/B ratio of 0.55, the current P/B ratio is about -54.10% higher. Bolt Biotherapeutics Inc (BOLT) has a Forward Free Cash Flow (FCF) yield of approximately -519.96%. Compared to its 3-year average FCF yield of -229.18%, the current FCF yield is approximately 126.88% lower. Relative to its 5-year average FCF yield of -163.53% , the current FCF yield is about 217.95% lower.

0.27

P/B

Median3y

0.31

Median5y

0.55

-519.96

FCF Yield

Median3y

-229.18

Median5y

-163.53

Competitors Valuation Multiple

The average P/S ratio for BOLT's competitors is 149.85, providing a benchmark for relative valuation. Bolt Biotherapeutics Inc Corp (BOLT) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of 41.49%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BOLT.O

Bolt Biotherapeutics Inc

Aprea Therapeutics Inc

Dogwood Therapeutics Inc

Loss

9.54M

Performance Decomposition

Market capitalization of BOLT decreased by 60.62% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 1.28M to 1.80M.

The secondary factor is the P/E Change, contributed -30.66%to the performance.

Overall, the performance of BOLT in the past 1 year is driven by Revenue Growth. Which is more sustainable.

41.49%

1.28M → 1.80M

Revenue Growth

-71.45%

-1.66K → -474.56

Margin Expansion

-30.66%

-0.30 → -0.21

P/E Change

-60.62%